Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (9264)	3/18/1999 12:00:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

Wake up, and riddle me this! Why is it impossible to get focus on the problem resulting from using the mortality of the treatment arm as part of a total mortality target? If one is saying we need x number of deaths before a trial can be ended, it would seem that the more successful the treatment arm is, and the longer it would take to complete a trial. Why would it not make more sense to simply say when we see x amount of mortality in the placebo arm the trial can be ended? Now if someone establishing the trial requirements said we need to see x deaths and we don't care which arm they come from then I understand why a company would agree to this. But, I would still not understand why a lower target just for the placebo arm could not have been used.